The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Acute myeloid leukemia
- Buy Rating Affirmed for Curis’s Emavusertib Following Promising Leukemia Study Results
The study’s updated data reported notable success in treating patients with relapsed or refractory acute myeloid leukemia (AML), particularly within the FLT3 mutation cohort, where a substantial ...
- Curis Announces Additional Data from TakeAim Leukemia Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from the ...
- Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months –– Topline data expected in early 2025 –– Breakthrough Therapy ...
- Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
The average age of the patients was 82. About 77% had been newly diagnosed with AML while 10% had relapsed or hard-to-treat AML. About 20% to 25% of all treated patients experienced prolonged survival ...
- Level of MRD Before Transplant Linked to Risk of Relapse, Death in FLT3-ITD AML
A higher level of MRD before transplant is associated with a higher risk of relapse and death in patients with FLT3-ITD AML, data suggest.
Go deeper with Google Headlines on:
Acute myeloid leukemia
[google_news title=”” keyword=”acute myeloid leukemia” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
AML
- Canadian parliament adds to TD Bank AML scrutiny
The planned meeting represents the latest scrutiny Canada’s second largest lender has faced regarding alleged deficiencies in its anti-money laundering (AML) program. The Financial Transactions and ...
- Hutchmed begins registrational phase III trial of HMPL-306 for patients with IDH1- and/or IDH2-mutated relapsed/refractory AML in China
Hutchmed begins registrational phase III trial of HMPL-306 for patients with IDH1- and/or IDH2-mutated relapsed/refractory AML in China: Hong Kong, Shanghai Wednesday, May 15, 202 ...
- Etops adopts AML and KYC analytics capabilities from Polixis
Etops, a leading Swiss-headquartered WealthTech, announces strategic partnership with Polixis, the leading AML and KYC data provider. The collaboration signifies a pivotal step towards developing the ...
- Aml Ameen: A Black Man in Full
Aml Ameen is primed for international stardom. Already a familiar face to many, with notable roles in streaming hits like Rustin, Boxing Day, and Yardie, the British-born actor's profile has been on a ...
- Buy Rating Affirmed: Shattuck Labs’ Promising Clinical Developments in HR-MDS and AML Treatment
Shattuck Labs (STTK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum ...
Go deeper with Google Headlines on:
AML
[google_news title=”” keyword=”AML” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]